The molecular basis of neoplastic B-cell growth is complex and poorly understood. Cytokines have been postulated to contribute to neoplastic cell growth, and many in vitro studies have confirmed this prediction, but little is known about the in vivo role of these growth factors. We have examined the production of interleukin-l4 (IL-14) ( Other studies had shown that high-grade, Burkitt's (small noncleaved cell in International Working Formulation) lymphoma cell lines, such as Namalva, constitutively secrete a high molecular weight (HMW), BCGF which is upregulated after stimulation with phytohemagglutinin (PHA), with a similar spectrum of growth factor activitie~.~.~ We have recently cloned the HMW-BCGF gene from Namalva cells and now refer to it as interleukin-l4 (IL-14).6 Antibodies to IL-I4 (HMW-BCGF') and its receptor IL-14R (BCGF-R)* have also been described and characterized. We have hypothesized that anomalous secretion of these BCGFs in neoplastically transformed NHL-B, might establish an autocrine or paracrine mechanism by which NHL-B cells escape from the normal growth regulation.' While BCGF activities have been readily demonstrated in vitro, there has been little evidence supporting a role for BCGFs in the pathophysiology of the aggressive forms of NHL-B in vivo. In this report, we describe studies showing that IL-14 is present in the effusion fluids of NHL-B patients with high tumor cell burdens, and that freshly isolated NHL-B cells from these effusions secrete and respond to IL-14 (HMW-BCGF). The patients were selected for high lymphoma cell number without significant numbers of mesothelial or inflammatory cells. lymph~cytes.~~'~.'' For these studies, a microbead methodology was usedt6," (Quantum Simply Cellular [QSC]; Flow Cytometry Standards, Research Triangle Park, NC) to determine the number of bound antibody molecules per cell.'* A calibrated standard curve is used to convert linear histogram channels into molecular equivalents of soluble fluorochrome (MESF). Cell surface indirect labeling was performed using BA5 (1 pg120 pL), and a goat F(ab'), antimouse IgG fluorescein isothiocyanate (Caltag, San Francisco, CA) secondary label. Cells were incubated at 4°C for 45 minutes. Fifty microliters of QSC beads was labeled with the primary and secondary antibodies under the above conditions. A standard curve was constructed from the quantities of BA5 (MoAb) bound to the calibrated beads. The number of BA5 molecules bound per NHL-B cell were determined using Flow Cytometry Standards software. Anti-p activated normal B cells were used as positive controls, and peripheral blood T cells as negative controls.
Establishment of lymphoma cell lines.
Freshly obtained lymphoma cells were cultured at varying concentrations in RPMI 1640 and 20% fetal calf serum (FCS) (Hyclone, Ogden, UT) at 37°C in an incubator containing 5% COz. Cell lines were established as previously described," using exogenously provided purified IL-14 to overcome spontaneous apoptosis occurring in the initial weeks of cell culture. The cell lines displayed identical immunophenotypes to the original cytology specimens.
Purification of IL-14 from effusion fluids or conditioned media. After treatment with protease inhibitors, and passage through 0.80-p and 0.22-p filters, effusion fluids were equilibrated through a PD-10 column (Pharmacia, Piscataway, NJ) into 50 mmolfL TRIS, pH 8.0, and loaded onto 20 mL diethylaminoethyl (DEAE) Sephacel columns (Pharmacia) preequilibrated with 50 mmoVL TRIS pH 8.0. BCGF was eluted by a 1 to 500 mmolL linear NaCl gradient run at 60 mL/h. Fractions (2.5 mL) were collected and assayed for BCGF activity at 10% vol/vol per well on either autochthonous NHL-B cells or normal peripheral blood donor B cells activated by F(ab'h anti-IgM (anti-p) antibodies. L 1 4 from cultured NHL-B cells was purified essentially according to the methods described by Ambrus et The active fractions were then concentrated and tun on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for silver staining and for Western blotting.
lmmunologic identification of IL-14 (HMW-BCGF) in effusion jluids. Effusions were fractionated by DEAE chromatography. Fractions with BCGF activity were collected, pooled, and subjected to Western blot analysis and immunoprecipitation with monospecific anti-IL-14 polyclonal antibodies8 Western blots were performed, as previously described.' Briefly, 80 pL of the peak fractions containing BCGF activity were separated on a IO% SDS-PAGE gel onto nitrocellulose and blocked with blotto (3% powdered milk, 50 mmolL Tris, 0.9% NaCI, 0.05% Tween 20, 0.02% NaN3, pH 7.8) at 4°C overnight. Blots were then incubated with monospecific anti-IL-14 polyclonal antibody (1 :4,000) for 2 hours at room temperature. After washing, the filters were incubated with '2'I-labeled goat-antirabbit Ig antisera (1 : 1,000) (Amersham, Arlington Heights, IL) for 1 hour and exposed on x-ray film (Kodak XAR, Rochester, NY). Immunoprecipitation was performed by incubating active peak DEAE fractions at 4°C with 40 pg of purified anti-IL-14 (HMW-BCGF) IgG or preimmune IgG (negative control). The samples were then incubated with preequilibrated Protein A sepharose beads (50 pL) (Sigma) for 1 hour. Beads and supernatant were separated using a Millipore 0.22-p microfuge filter. The beads were extensively washed, and 5X sample buffer was added to bound (beads) and unbound (supematant) proteins, and fractions were run on 10% SDS-PAGE, transferred to nitrocellulose, and analyzed by Western blots using alkaline phosphatase conjugated anti-lL-14 antibody for detection.
ln vitro production of growth factor by NUL-B cells from efision jluids. Fresh NHL-B cells pelleted from effusion fluids were Erosetted and spun through FicollMypaque (FM) (Sigma) gradients, washed, and cultured for 48 hours in the presence or absence of PHA (0.75% vol/vol) (GIBCO, Grand Island, NY) in RPMI 5% FCS for 48 hours. Control NHL-B cells were cultured in FCS, 5% in RPMI. Established cell lines from NHL were treated similarly and used as positive controls. Supernatants from cell cultures were clarified through 0.22-pm filters and concentrated in an Amicon concentrator using YM-IO membranes. Samples were then passed through a PD-10 column (Pharmacia) and subsequently tested for BCGF activity, as described below.
In virro growth factor assays. Growth factor assays for BCGF activity were performed as previously describedI3." using anti-p stimulated B lymphocytes obtained from normal donor peripheral blood mononuclear cell populations. B cells were purified using SRBC rosetting and separation on F/H, followed by plastic adherence to remove monocytes. Residual T cells or monocytes were removed magnetically, if necessary, by further treatment with cocktails of MoAb (eg, CD2,4, 14), followed by magnetic beads attached to antimouse Ig (Dynal, Great Neck, NY). B cells used were greater than 95% CD19 and sIg positive. Triplicate microtiter wells containing 1 X 10' anti-y B cells were exposed to different concentrations of growth factor containing fluids or column fractions. 'HThymidine uptake was determined over the last 18 hours of a 96-hour culture period, as previously described.'.'' Freshly obtained patient NHL-B cells were used in similar assays to assess response to exogenously provided growth factors, including IL-14?.' IL-2 (rIL-2; Cetus-Chiron, Emeryville, CA), 1L-4 (rIL-4), or IL-6 (rIL-6), Genzyme, Cambridge, MA.
Specific antibody blocking of HMW-BCGF (IL-14) activity in ejfu-.?ion jluids and in vitro culture supernatants.
Partially purified BCGF activity (pooled DEAE active fractions) from freshly obtained effusion fluids were concentrated 1OX through a 10,000 molecular weight cutoff membrane (Amicon Centriprep 10) and desalted into RPMI media with a PD 10 column (Pharmacia). Conditioned media (CM) from cultures of freshly obtained NHL-B cells were concentrated l o x in a similar fashion. Anti-IL-14 polyclonal IgG antibody (4 mg) or preimmune control rabbit IgG was bound to 500 pL bed volume of RPMI-equilibrated Protein A Sepharose beads (Sigma). A total of 500 pL of the concentrated active fractions (effusion fluids or CMs) were incubated with the antibody bound or control Igbound beads for 12 hours at 4°C. The supernatants were then passed through microfuge filter units (Ultrafree MC; 0.45 pm; Millipore, Bedford, MA), and immediately assayed for growth factor activity.
IL-14 gene expression una1ysi.s using reverse transcriptase-poly-merase chair? reaction (RT-PCR).
Freshly obtained NHL-B cells from effusion fluids were processed as described above, and total or poly A RNA was extracted and cDNA synthesized with reverse transcriptase, using GlBCO BRL (Gaithersburg, MD) Superscript PreAmplification Kit. Oligonucleotide primers based on the IL-14 cDNA sequence were synthesized as follows: forward (147) TCC-TGACCAGCACATV and reverse (R I41 2) AGCAAGGACCTA-CAACAGCAGCCATCC.7 PCR analysis was performed using a Thermo Cycler 480 (Perkin-Elmer-Cetus, Norwalk, CT), Taq polymerase, and dNTPs. Thirty-five cycles of amplification were used for 1 minute 94°C denaturation, I minute at 55°C annealing, and 2 minutes at 72°C. The amplified material was run on a 1.2% agarose gel, stained with ethidium bromide and photographed under ultraviolet (UV) illumination. Amplified bands were confirmed by Southern blot analysis using a radioactively labeled IL-14 cDNA probe. 
RESULTS

Characterization of tumor cells from lymphomatous effusions in patients with aggressive NHL-B.
Effusion fluids from NHL-B patients were processed. The tumor cells were initially pelleted from the effusion fluids with the fluid and cellular components analyzed separately. Microscopically, all cases were diagnosed as large cell, non-Hodgkin's lymphoma on hematoxylin and eosin (H&E)-stained cytospin preparations (Fig 1 A) . Immunophenotyping by flow cytometry confirmed that the lymphoma cells were in each case aggressive (diffuse large cell) NHL-B (Table 1) . Controls consisted of effusions from patients with low-grade, NHL-B (Fig I B) , or from patients with nonhematologic neoplasms (eg, breast carcinoma). Cytogenetic analysis of NHL-B cells from the effusions showed aneuploid karyotypes of the hyperdiploid or hypertetraploid type, with abnormalities present in chromosome 14 of the nonrandom type (t14; 18) (Fig  2A) or indeterminate type in 3 of 4 patients and deletions in chromosome 6q in 2 of 4 patients (Fig 2B) . Multiple random structural abnormalities were also observed in each of the cases. Cell lines were established from the NHL-B cells recovered from the effusion patients in each of the four patients who had identical immunophenotypic and cytogenetic profiles to the originally obtained lymphoma cell specimens. IL-14 (HMW-BCGF) activity in effusion juids from aggressive NHL-Bpatients. In vitro growth factor activity for autochthonous NHL-B cells was present in the chromatographically fractionated effusion fluids, as shown in Fig 3A. BCGF activity determined on anti-p stimulated peripheral blood B lymphocytes was found in the same effusion fluids when DEAE fractions of NHL-B patients' fluids were analyzed in Fig 3B. No BCGF activity was present in the control patients' fluids ( Fig 3B, patients a through c) . These findings suggest that the same factor(s), might be stimulating both the normal and lymphoma cells. , as has been previously described.* Production of IL-14 activity by freshly obtained NHL-B cells from lymphomatous effusions. To further verify that the growth factor activity present in the effusion fluids was produced by the NHL-B cells present in these fluids and not by a contaminating accessory cell (eg, mesothelial cells), the pelleted lymphoma cells were extensively washed, and the contaminating T lymphocytes were removed by E-rosetting. Monocytes/macrophages, and mesothelial cells (which were particularly scarce in these patients' fluids) were deleted by plastic adherence. NHL-B cells accounted for >98% of the final lymphoma cell population by flow cytometric and cytopathologic analysis. The NHL-B cell population was then cultured in 5% FCS with or without PHA for 48 hours, concentrated, and assayed for growth factor activity as above. The B-cell proliferative activity contained in the supernatants of the patients NHL-B cell populations is shown in Fig 5A. Patients whose fluids contained BCGF activity also had NHL-B cells that produced BCGF activity in vitro. In Fig 5B, similar results are shown for established NHL-B cell lines that we had derived from other patients with similar aggressive (intermediate or high-grade) NHL-B, as well as the Namalva (BL) cell line, from which IL-14 was originally described.
In vitro growth stimulation of NHL-B cells from effusion fluids. To determine the responsiveness of the freshly-obtained NHL-B cells from the effusion fluids to putative autocrine growth factor(s)/BCGFs produced by these lymphoma cells, we exposed the tumor cells to purified 1L-14 in vitro, obtained from one of the patient's cell lines (patient MS) (Fig 6A) .
In Fig 6B, it can be seen that in two of the patients, NHL-B cells responded actively to exogenously provided IL-14, but not to other putative H-cell growth promoting cytokines, such as IL-6. 1L2 and L 4 (rJL2 and rlL-4), which are also putative BCGFs, also failed to stimulatc the NHL-B cells (Fig K ) . One of the patients had a very high spontaneous prolifcration that was not significantly increased with the addition of exogenous L 1 4 or other putative B-cell stimulatory cytokincs, but was inhibited by r L 4 (data not shown).
lmnzunologic identl\iccllion of' I L -14 in putirnt c/fiu.ciom by Western blot urd itn,nlltlor~urc.ii?itntion. cma1y.ri.r. To confirm that the proljfcration-indllcing biologic activity present in the effusion fluids was 112-14, WC analyLed the fluids before and after imlnllnoprecipitation by Western blot using a monospecific polyclonal antiscra to IL,-14, as described previously.' As shown in Fig 7, the anti--ll,-14 antisera recogniLed an -60-kll band in both untreated or anti-lL-l4 immunoprecipitatcd effusion fluids known to have BCGP activity. Control effusion, lacking KCGF activity, did not contain IL-14. The broadness of the IL-14 bands is most likely secondary to variable glycosylation.
Removcd 01 BCGF uclivily ,fuonz elfiusion ,fluid,s a t d NHL-
h ' conrditioacd n d i u with trnli-IL-l4 (HMW-BCGP) clntihodics.
If autocrine growth fixtor activity mediated by 11,-14 is responsible for lymphoma cell growth, as we have hypothesized, it should be possiblc to block growth stimulation with specific antibodies. To address this point, we treated thc freshly obtained effusion fluids and CM, obtained after in vitro culture of purified N H L B cells, with anti-IL-14 antibody attached to sepharosc beads. In Fig X, it can be seen that when eiTusion fluids (XA) and CM (XB) were treated with antibody-bound beads for 12 hours at P C , greater than 70%) of the growth factor activity was rcmoved in both instances. Effusion fluids and CM treated with COIItrol (nonimmune) rabbit IgG-coli~iugutcd beads, had less than 5% of the growth factor xtivity rcmoved. 
Histograms showing BA5 bindGo B c e l l s a n t i -" B cells scrambled IL-14 PT-AS0 showed less than 20% inhibition at a dose of 30 pmol/L (Fig 10) . The viability of the NHL-B cells was greater than 95% at time zero, but diminished to 50% to 60% in IL-14 PT-AS0 treated cultures at 72 hours, whereas media controls were greater than 80% viable after 72 to 96 hours.
Expression of the. IL-I4 (HMW-HCGP) genr in NHL-B c~r l l s isolated ,from
DISCUSSION
Regulation of tumor cell growth in patients with malignant lymphoma is clearly an area of central importance, both biologically and therapeutically. A number of studies, particularly in aggressive intermediate (large cell) and high-grade NHL-B, where cell kinetics were evaluated by flow cytometry, have shown that this parameter relates directly to patient , showing an approximately 60-kD protein on silver stained SDS-PAGE and Western blot using a monospecific anti-IL-14 antibody. This natural product cytokine was used for experiments involving exogenous IL-14 B-cell stimulation. Recombinant IL-14 was produced in CVl-EBNA cells using pEBVHis (Invitrogen, San Diego, CA) and purified on nickel sepharose, as described. Native 11-14 was purified as described earlier. A total of 100 ng recombinant and native IL-14 were separated in 10% SDS-PAGE gels, transblotted t o PVDF membranes, and identified with anti-IL-14 antibodies as described earlier. Cell lines were derived from these aggressive B-cell lymphomas, consistent with our previous experience. Earlier Most of our patients (including those reported here) begin with nodal lymphomas that progress to lymphomatous effusions, often after relapse postchemotherapy. These cell lines, like the freshly isolated NHL-B cells from the patients, express IL-14 mRNA, secrete IL-14, and proliferate in response to IL-14. This suggests that IL-14 may be an autocrine growth factor for these lymphomas in vivo, although other factors could also be involved with growth regulation. Because exogenous IL-14 also stimulated NHL-B cell proliferation in vitro, use of IL-14 may be paracrine, as well as autocrine. The demonstration of a possible autocrine/paracrine growth factor (AGF) for aggressive (intermediate and high-grade) NHL-B suggests that a variety of potential biologic approaches to therapy may be tried for these lymphomas. One might be the use of antisense oligonucleotide based on IL-14, as demonstrated in this study. This is of particular importance for patients, such as those described here, as these patients were refractory to further chemotherapy or other salvage treatments, resulting in an extremely poor prognosis and consequently very short survival times.
The antisense studies (AS) involving the IL-14 gene, may be of significant interest in regard to the pathogenesis of these NHL-B cases, particularly when considered together with the other studies showing the involvement of IL-14 in stimulating NHL-B cell proliferation. They used IL-14 PT-AS0 that were designed for efficient uptake"-" optimal oligonucleotide size, and sequence site (initiation codon) specificity," as well as resistance to nuclease activity (sulphur substitution in phosphate backbone)." Specific inhibition of 
